Endocrinology, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
Pediatric Endocrinology, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
Front Endocrinol (Lausanne). 2021 Apr 2;12:619895. doi: 10.3389/fendo.2021.619895. eCollection 2021.
The prevalence of idiopathic oligozoospermia has been esteemed as high as 75%. An Italian survey has reported bilateral testicular hypotrophy in 14% of final-year high school students. The search for determinants of testicular growth in childhood is important for the primary prevention of spermatogenic failure. Therefore, this retrospective study aimed to evaluate the testicular growth and pubertal onset in deficient children treated recombinant human growth hormone (rhGH). To accomplish this, the clinical charts of 93 patients with GH deficiency (GHD) were carefully reviewed. Their mean age at the time of diagnosis was 11.2 ± 2.4 years. rhGH was administered for 44.0 ± 22.4 months, and the onset of puberty was recorded after a mean of 25.8 ± 22.4 months from the first rhGH administration. As expected, serum insulin-like growth factor 1 (IGF1) levels increased significantly after treatment. Before rhGH therapy, the Tanner stage was I in 59 out of 70 boys (84.3%), II in 8/70 (11.4%), III in 3/70 (4.3%). No one was on stage IV or V. The mean Tanner stage was 1.19 ± 0.51. At the last visit, the Tanner stage was I in 8/72 boys (11.1%), II in 6/72 (8.3%), III in 6/72 (8.3%), IV in 16/72 (22.2%), and V in 36/72 (50.0%). After a mean of 44.0 ± 22.4 months of rhGH treatment, the mean Tanner stage was 4.05 ± 1.30. Patients treated with rhGH showed a significant testicular volume (TV) growth over time, whereas no growth was observed in age-matched but not yet treated patients, even when the age was compatible with a spontaneous start of puberty. The multivariate regression analysis showed that the duration of treatment and the mean rhGH dose significantly predicted the percentage of TV increase. In contrast, age, serum FSH, and IGF1 levels, and final rhGH dose did not impact TV growth over time. In conclusion, these findings suggest that GH may play a role in testicular growth and pubertal onset, despite the descriptive nature of this study. Further properly designed studies are needed to confirm these findings. This knowledge may be useful to implement the diagnostic-therapeutic algorithm in case of a lack of testicular growth in childhood.
特发性少精子症的患病率估计高达 75%。一项意大利调查显示,在高三学生中,有 14%的人双侧睾丸萎缩。因此,寻找儿童期睾丸生长的决定因素对于原发性生精失败的预防至关重要。因此,这项回顾性研究旨在评估接受重组人生长激素(rhGH)治疗的生长激素缺乏症(GHD)儿童的睾丸生长和青春期启动情况。为了实现这一目标,仔细审查了 93 例生长激素缺乏症(GHD)患者的临床病历。他们的诊断时平均年龄为 11.2 ± 2.4 岁。rhGH 治疗 44.0 ± 22.4 个月,平均在首次 rhGH 治疗后 25.8 ± 22.4 个月记录青春期开始。如预期的那样,治疗后血清胰岛素样生长因子 1(IGF1)水平显著增加。rhGH 治疗前,70 名男孩中有 59 名(84.3%)处于 Tanner 分期 I 期,8 名(11.4%)处于 Tanner 分期 II 期,3 名(4.3%)处于 Tanner 分期 III 期。没有人处于 IV 期或 V 期。平均 Tanner 分期为 1.19 ± 0.51。最后一次就诊时,72 名男孩中有 8 名(11.1%)处于 Tanner 分期 I 期,6 名(8.3%)处于 Tanner 分期 II 期,6 名(8.3%)处于 Tanner 分期 III 期,16 名(22.2%)处于 Tanner 分期 IV 期,36 名(50.0%)处于 Tanner 分期 V 期。rhGH 治疗 44.0 ± 22.4 个月后,平均 Tanner 分期为 4.05 ± 1.30。接受 rhGH 治疗的患者睾丸体积(TV)随时间显著增长,而未接受治疗但年龄匹配的患者则没有增长,即使年龄与自发青春期开始相匹配。多变量回归分析显示,治疗持续时间和平均 rhGH 剂量显著预测 TV 增加的百分比。相比之下,年龄、血清 FSH 和 IGF1 水平以及最终 rhGH 剂量对 TV 随时间的增长没有影响。总之,尽管这项研究具有描述性,但这些发现表明 GH 可能在睾丸生长和青春期启动中发挥作用。需要进一步进行适当设计的研究来证实这些发现。这些知识可能有助于在儿童期睾丸生长不足的情况下实施诊断-治疗算法。